Prednisone
Prednisone (prednisone) is a small molecule pharmaceutical. Prednisone was first approved as Paracort on 1982-01-01. It is used to treat adrenal insufficiency, allergic conjunctivitis, allergic rhinitis, ankylosing spondylitis, and asthma amongst others in the USA. The pharmaceutical is active against glucocorticoid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Show 8 more
Trade Name
FDA
EMA
Prednisone (discontinued: Cortan, Deltasone, Deltome, Fernisone, Liquid pred, Meticorten, Orasone, Paracort, Prednicen, Prednisone, Rayos, Servisone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Prednisone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RAYOS | Horizon Therapeutics Public | N-202020 DISCN | 2012-07-26 | 3 products, RLD |
| PARACORT | Pfizer | N-010962 DISCN | 1982-01-01 | 1 products |
| DELTASONE | Pharmacia & Upjohn | N-009986 DISCN | 1982-01-01 | 5 products, RLD |
| PREDNISONE | Roxane Laboratories | N-017109 DISCN | 1982-01-01 | 1 products |
| METICORTEN | Merck & Co | N-009766 DISCN | 1982-01-01 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cortane-b | unapproved drug other | 2017-03-20 |
| deltasone | ANDA | 2018-11-02 |
| deltasone 5mg | ANDA | 2020-10-15 |
| p- pack prednisone 20mg, 7- day tapering dose pack | ANDA | 2025-02-11 |
| prednisone | ANDA | 2025-10-03 |
| prednisone prednisone | ANDA | 2025-07-14 |
| prednisone prednisone intensol | ANDA | 2025-04-22 |
| prednisone tablets, usp, 10 mg | ANDA | 2025-10-03 |
| prednisone tablets, usp, 10 mg prednisone tablets, usp, 20 mg prednisone tablets, usp, 5 mg | ANDA | 2025-08-15 |
| prednisone tablets, usp, 20 mg | ANDA | 2025-10-03 |
Show 2 more
Indications
FDA
EMA
Show 23 more
Agency Specific
FDA
EMA
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07E: Intestinal antiinflammatory agents
— A07EA: Corticosteroids acting locally
— A07EA03: Prednisone
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H02: Corticosteroids for systemic use
— H02A: Corticosteroids for systemic use, plain
— H02AB: Glucocorticoids, systemic
— H02AB07: Prednisone
HCPCS
Code | Description |
|---|---|
| G2112 | Patient receiving <=5 mg daily prednisone (or equivalent), or ra activity is worsening, or glucocorticoid use is for less than 6 months |
| G2113 | Patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity |
| G9468 | Patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills |
| G9470 | Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg |
Clinical
Clinical Trials
2381 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 1 | 9 | 2 | 1 | 1 | 13 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | 2 | — | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 2 | — | — | — | 2 |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | 1 | 1 | — | — | — | 1 |
| Bone marrow diseases | D001855 | — | — | 1 | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
| Peripheral nervous system diseases | D010523 | — | G64 | — | 1 | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | 1 | — | — | — | 1 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 1 | — | — | — | 1 |
| B-cell lymphoma | D016393 | — | — | — | 1 | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Prednisone |
| INN | prednisone |
| Description | Prednisone is a synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid. It has a role as a prodrug, an anti-inflammatory drug, an antineoplastic agent, an immunosuppressive agent and an adrenergic agent. It is a 20-oxo steroid, an 11-oxo steroid, a 21-hydroxy steroid, a 17alpha-hydroxy steroid, a glucocorticoid, a 3-oxo-Delta(1),Delta(4)-steroid, a primary alpha-hydroxy ketone, a tertiary alpha-hydroxy ketone and a C21-steroid. |
| Classification | Small molecule |
| Drug class | prednisone and prednisolone derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO |
Identifiers
| PDB | — |
| CAS-ID | 53-03-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL635 |
| ChEBI ID | 8382 |
| PubChem CID | 5865 |
| DrugBank | DB00635 |
| UNII ID | VB0R961HZT (ChemIDplus, GSRS) |
Target
Agency Approved
NR3C1
NR3C1
Organism
Homo sapiens
Gene name
NR3C1
Gene synonyms
GRL
NCBI Gene ID
Protein name
glucocorticoid receptor
Protein synonyms
Nuclear receptor subfamily 3 group C member 1, nuclear receptor subfamily 3 group C member 1 variant hGR-B(54), nuclear receptor subfamily 3 group C member 1 variant hGR-B(77), nuclear receptor subfamily 3 group C member 1 variant hGR-B(93), nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
Uniprot ID
Mouse ortholog
Nr3c1 (14815)
glucocorticoid receptor (Q61629)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Rayos – Horizon Therapeutics Public
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Prednisone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 22,541 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
193,808 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use